Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07291180 · ClinicalTrials.gov registry record · NA
A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis
A NA study of Colorectal Adenocarcinoma and Appendiceal Cancer, sponsored by Yale University.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07291180: Recruiting NA study of Colorectal Adenocarcinoma and Appendiceal Cancer, sponsored by Yale University.
NCT07291180 is a NA study of Colorectal Adenocarcinoma and Appendiceal Cancer that is actively recruiting participants, run by Yale University. The registered enrollment target is 20 participants, below the 318-participant average among 19 other Colorectal Adenocarcinoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07291180, a NA study of Colorectal Adenocarcinoma and Appendiceal Cancer, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the role of mass-based response testing (MRT) to select and deliver personalized hyperthermic intraperitoneal chemotherapy (HIPEC) regimens to patients with peritoneal metastasis (PM) from high-grade appendiceal adenocarcinomas (HGAA) and colorectal cancer (CRC).
Primary Outcome
Feasibility is defined as the percentage of treatment naïve and pretreated patients who successfully receive drug screening results within one week of tissue sampling from at least one peritoneal biopsy. This means that the test has enough tumor cell viability and purity to come back with specific results indicating sensitivities of HIPEC drugs and does not give an inconclusive result (due to insufficient tissue sample).
Conditions Studied
Interventions
- DEVICE Mass-based response testing (MRT)
Study Locations (1)
Connecticut
- Yale New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-03 |
| Est. Completion | 2027-12 |
| Phase | NA |
What NCT07291180 shows while recruiting
NCT07291180 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 318-participant average among 19 other Colorectal Adenocarcinoma trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Colorectal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Mass-based response testing (MRT) is the first listed.
NCT07291180 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT07291180 about?
NCT07291180 is a clinical study titled "A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis". This study will evaluate the role of mass-based response testing (MRT) to select and deliver personalized hyperthermic intraperitoneal chemotherapy (HIPEC) regimens to patients with peritoneal metastasis (PM) from high-grade appendiceal adenocarcinomas (HGAA) and colorectal cancer (CRC).
What is the current status of trial NCT07291180?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2026-03. Estimated completion is 2027-12.
What conditions does trial NCT07291180 study?
This clinical trial studies the following conditions: Colorectal Adenocarcinoma, Appendiceal Cancer, Peritoneal Metastases.
What interventions are being tested in trial NCT07291180?
The interventions under investigation include: Mass-based response testing (MRT) (DEVICE).
Who is sponsoring clinical trial NCT07291180?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07291180 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07291180's enrollment target sits among peer trials
20 18th of 19 higher than 2 of 19 other Colorectal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RECRUITING · Phase 1
-
Early Onset Colorectal Cancer Detection
RECRUITING
-
Stage II/III Colorectal Cancer Recurrence
RECRUITING
-
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RECRUITING · Phase 1
-
Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia